Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Neurocrine Biosciences (NBIX)

Neurocrine names Eiry Roberts chief medical officer, replacing Sanjay Keswani

Neutral Impact 3 of 5 leadership Written later

Neurocrine Biosciences appointed Eiry W. Roberts, M.D., as Chief Medical Officer effective September 28, 2026, succeeding Sanjay Keswani, M.D., whose service ended September 25, 2026 by mutual agreement. The filing says Dr. Roberts will receive a base salary of $825,000, a target bonus of 60% of base pay, and about $1.25 million in target equity grants, and that Dr. Keswani will receive severance under the company's Executive Severance Plan.

Key points

  • Dr. Keswani's service as Chief Medical Officer ended September 25, 2026, by mutual agreement with the Board.
  • Dr. Roberts was appointed Chief Medical Officer effective September 28, 2026, with an annual base salary of $825,000 and a target bonus of 60% of base pay for 2026.
  • Target equity grants total about $1.25 million: stock options of about $625,000, restricted stock units of about $250,000, and performance-vesting restricted stock units of about $375,000.
  • The final Employment Agreement is expected to be filed with the Form 10-Q for the quarter ending September 30, 2026.

The filing

CompanyNeurocrine Biosciences (NBIX)
Form8-K, current report
Filed with the SECSep 28, 2026, 4:20 PM ET
Accession number0000914475-26-000045

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 7:01 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 28, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.